Otlertuzumab (TRU‐016) is a humanized monoclonal antibody that targets CD37 designed for the treatment of cancer. This drug was developed by Emergent BioSolutions...
2 KB (105 words) - 14:18, 26 September 2023
type 1 Otilimab mab human GMCSF osteoarthritis, rheumatoid arthritis Otlertuzumab mab humanized CD37 cancer Oxelumab mab human OX-40 asthma Ozanezumab...
135 KB (4,054 words) - 22:35, 2 July 2024
Matuzumab§ Milatuzumab§ Naxitamab Nimotuzumab† Obinutuzumab Ocaratuzumab§ Otlertuzumab§ Onartuzumab§ Oportuzumab monatox† Parsatuzumab§ Pertuzumab Pinatuzumab...
5 KB (368 words) - 22:00, 19 October 2020
Matuzumab§ Milatuzumab§ Naxitamab Nimotuzumab† Obinutuzumab Ocaratuzumab§ Otlertuzumab§ Onartuzumab§ Oportuzumab monatox† Parsatuzumab§ Pertuzumab Pinatuzumab...
4 KB (241 words) - 11:41, 22 April 2022
Matuzumab§ Milatuzumab§ Naxitamab Nimotuzumab† Obinutuzumab Ocaratuzumab§ Otlertuzumab§ Onartuzumab§ Oportuzumab monatox† Parsatuzumab§ Pertuzumab Pinatuzumab...
3 KB (129 words) - 01:04, 19 July 2023